title: Lenalidomide-associated hemolytic anemia.
authors: a Division of Hematology/Oncology, Department of Medicine , University of North Carolina , Chapel Hill , NC , USA.
authors: Ming Y
authors: MY
authors: Lim
authors: b Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine , University of North Carolina , Chapel Hill , NC , USA.
authors: Jay S
authors: JS
authors: Raval
authors: a Division of Hematology/Oncology, Department of Medicine , University of North Carolina , Chapel Hill , NC , USA.
authors: Kristy L
authors: KL
authors: Richards
authors: a Division of Hematology/Oncology, Department of Medicine , University of North Carolina , Chapel Hill , NC , USA.
authors: Joshua F
authors: JF
authors: Zeidner
authors: a Division of Hematology/Oncology, Department of Medicine , University of North Carolina , Chapel Hill , NC , USA.
authors: Matthew C
authors: MC
authors: Foster
mesh_terms: D000368:Aged; D000743:Anemia, Hemolytic / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy; D008297:Male; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D013792:Thalidomide; D000077269:Lenalidomide